Japan Said To Lack Infrastructure For Major Biotech Industry – Takeda President
This article was originally published in PharmAsia News
Executive Summary
Japan lacks the infrastructure and funding necessary to have a major biotechnology industry, according to the president of Takeda Pharmaceutical. Yasuchika Hasegawa said that moving beyond Japan's current status of limited biotech efforts requires more bioventure funds than the nation has and said the industry also is restricted by the current tax system and the lack of enough bio clusters. Japan's biotech ventures are characterized by their focus on just a few drugs or technologies in their pipelines, and Hasegawa said that moving beyond that would require being able to generate new revenue sources continually. (Click here for more - a subscription may be required